Alnylam Pairs Its RNAi Expertise with Inceptive's AI in Deal Worth Up to $2B
Alnylam knows RNAi better than almost anyone, but designing new drugs is still slow and expensive. The bet here is to let Inceptive's foundation model generate designs trained on Alnylam's proprietary data, and see whether that actually shortens the path to patients. The headline number is milestone-dependent, so there's no proof yet that it works.
practitioners › $30M upfront, up to $2B total tied to milestones, announced June 3, 2026.
investors.alnylam.com →